Holen Sie sich die Stockscreener-App
29.59
0.51%
0.15
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$29.44
Offen:
$29.72
24-Stunden-Volumen:
11.69M
Relative Volume:
0.38
Marktkapitalisierung:
$168.65B
Einnahmen:
$63.32B
Nettoeinkommen (Verlust:
$7.52B
KGV:
22.69
EPS:
1.3043
Netto-Cashflow:
$9.48B
1W Leistung:
+4.63%
1M Leistung:
+7.76%
6M Leistung:
+8.71%
1J Leistung:
+22.12%
1-Tages-Spanne:
$29.42
$29.74
1-Wochen-Bereich:
$28.13
$29.88
52-Wochen-Spanne:
$23.62
$29.88
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
29.59 | 168.65B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,262.85 | 1.13T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
254.89 | 614.26B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
285.43 | 504.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
146.83 | 362.25B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.22 | 287.44B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-06 | Herabstufung | HSBC Securities | Buy → Hold |
| 2026-06-10 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2026-03-02 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Lilly, Pfizer, J&J win EU drug recommendations this month - Seeking Alpha
Layoffs Tracker: Kroger, Pfizer, Netflix and Amazon Hit This Week - Yahoo Finance
6 Blue Chip Stocks Trading Well Below Their Highs - The Motley Fool
2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends - The Motley Fool
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Pfizer Stock Hits 52-Week High: What's Going On? - Benzinga
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Pfizer stock hits 52-week high at $29.88 - Investing.com
The Pfizer Foundation and the American Red Cross: Strengthening Communities Year-Round - American Red Cross
Pfizer, Thermo Fisher Scientific And More: CNBC’s ‘Final Trades’ - Benzinga
PFIZER INC (PFE-USD.SW) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Pfizer Inc (Coinbase Tokenized Stock) Price | PFEc Price Today, Live Chart, USD converter, Market Capitalization - CryptoRank
Pfizer (NYSE:PFE): What Changes After Its Latest Company Update? - Kalkine Media
Pfizer (PFE) Gains As Market Dips: What You Should Know - Zacks Investment Research
Pfizer (PFE) Gains As Market Dips: What You Should Know - Yahoo Finance
Micro Pfizer Inc Stock Futures, (XPFE0Z26.CME) Stock Historical Prices & DataYahoo Finance - Yahoo! Finance Canada
Micro Pfizer Inc Stock Futures, (XPFE0Z26.CME) latest stock news and headlines - Yahoo Finance UK
Pfizer Inc Stock (PFE) Moved Up by 3.14% on Oct 14: Drivers Behind the Movement - TradingKey
Pfizer cuts another 150 jobs at Portage plant as demand slips - Crain's Grand Rapids Business
Pfizer’s Next‑Gen Pneumococcal Shot Enters Key Phase 3 Test, Extending Vaccine Growth Potential - TipRanks
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026 - Business Wire
Pfizer partners with Enodia Therapeutics in $500m drug deal - Pharmaceutical Technology
Pfizer (PFE) Pays Out Over 226% of Earnings and Trades at 36.7x Trailing Against 9.8 Forward. What Is the Yield Telling You? - Yahoo Finance
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research
Reasons Why Investors Should Consider Betting on Arvinas Stock - Zacks Investment Research
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules - BioSpace
Pfizer: The Earnings Test That Matters (NYSE:PFE) - Seeking Alpha
Guggenheim reiterates Pfizer stock rating ahead of Q3 earnings - Investing.com
Enodia Therapeutics Announces Research Collaboration And License Agreement With Pfizer Inc. To Develop Sec61-Targeting Small Molecules - marketscreener.com
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules - Business Wire
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Palvella Therapeutics (PVLA) and Mineralys Therapeutics, Inc. (MLYS) - The Globe and Mail
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock? - Zacks Investment Research
How to Play PFE Stock as Pfizer Cuts 300 Jobs - Barchart.com
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock? - Zacks Investment Research
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock? - TradingView
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research
Four analysts raise Pfizer targets. Pfizer stock gains 1.48 percent - ad-hoc-news.de
Urothelial Cancer Drugs Market to Expand at 19% CAGR, Exceeding $16 Billion by 2030, Pfizer Holds 28% Share - EIN News
Pfizer Inc. (PFE) options chain - Yahoo Finance UK
Pfizer Inc. (PFE) options chain - Yahoo Finance UK
Pfizer Inc Tokenized Stock (Coinbase) Price History and Historical Data - CoinMarketCap
Pfizer Is Trading at Less Than 10 Times Earnings. But Is the Stock Actually Cheap? - Yahoo Finance
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? - The Motley Fool
PFIZER INC (PFE-USD.SW) company profile and facts - Yahoo Finance Australia
PFIZER INC (PFE-USD.SW) stock price, news, quote and history - Yahoo Finance UK
Pfizer Inc. Research & Ratings | PFE - Barron's
Pfizer Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Pfizer Inc. (PFE.TO) Stock Forum & Discussion - Yahoo! Finance Canada
Top Research Reports for JPMorgan, ASML & Chevron - Zacks Investment Research
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pfizer Inc-Aktie (PFE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DAMICO JENNIFER B. | SVP & Controller |
Aug 05 '26 |
Sale |
25.40 |
3,278 |
83,261 |
28,611 |
| BLAYLOCK RONALD E | Director |
Aug 05 '26 |
Buy |
25.46 |
39,231 |
998,821 |
66,938 |
| Buckley Mortimer J | Director |
Aug 05 '26 |
Buy |
25.52 |
37,632 |
960,369 |
37,632 |
| DAMICO JENNIFER B. | SVP & Controller |
Jun 09 '26 |
Sale |
25.70 |
2,000 |
51,400 |
31,397 |
| SAHNI PAYAL | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
82,816 |
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
0.15%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):